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Abstract
Background and purpose: Data suggest that adipocytokines
and natural regulatory T (nTreg) cells play a pivotal role in
the immunopathogenesis of multiple sclerosis and the asso-
ciated inflammation. The purpose of this study was to eval-
uate selected adipocytokines and nTreg cells and to assess
their relationship with relapsing-remitting multiple sclerosis
(RRMS).
Material and methods: The study was conducted among 
25 patients with RRMS and 25 healthy individuals. Blood
samples were collected within two weeks after the beginning
of acute relapse of RRMS. The body mass index (BMI) of
each patient was calculated. Serum adipocytokine concentra-
tions were determined by ELISA and nTreg cells were eval-
uated using multicolour flow cytometry.
Results: Patients and controls had similar BMI, regardless 
of gender. Significantly higher leptin and resistin levels and
significantly lower adiponectin levels were found in patients
with RRMS in comparison to the control group (p < 0.0001).
The percentage of nTreg cells (p < 0.01) and the mean fluo-
rescence channel (MFC) of FoxP3 were significantly reduced
in patients with RRMS (p < 0.001). There was an inverse
correlation be tween leptin concentration and MFC of 
Evaluation of the relationship between leptin, resistin, adiponectin and natural
regulatory T cells in relapsing-remitting multiple sclerosis
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St reszc zen ie
Wstêp i cel pracy: Dane z piœmiennictwa sugeruj¹, ¿e w immu-
nopatogenezie i w przebiegu procesu zapalnego w stwardnie-
niu rozsianym szczególn¹ rolê mog¹ odgrywaæ adipocytokiny
oraz naturalne limfocyty regulatorowe T. Dlatego celem pra-
cy by³a ocena wybranych adipocytokin i limfocytów nTreg oraz
analiza zale¿noœci pomiêdzy nimi u chorych na stwardnienie
rozsiane w postaci nawracaj¹co-zwalniaj¹cej (RRMS).
Materia³ i metody: Badania przeprowadzono u 25 chorych
na RRMS. Krew pobrano w ci¹gu 2 tygodni od pocz¹tku
ostrego rzutu choroby. Grupê kontroln¹ stanowi³o 25 zdro-
wych osób. U ka¿dego pacjenta wyliczono wskaŸnik masy
cia³a (BMI). Stê¿enie adipocytokin oznaczono w surowicach
technik¹ ELISA. Ocenê immunofenotypu limfocytów nTreg
wy konano przy u¿yciu wielokolorowej cytometrii przep³y -
wowej.
Wyniki: Nie stwierdzono statystycznie istotnej ró¿nicy we 
wskaŸniku BMI pomiêdzy pacjentami z RRMS a grup¹ kon-
troln¹ niezale¿nie od p³ci. Wykazano znamiennie wiêksze stê -
¿enie leptyny i rezystyny oraz znamiennie mniejsze stê¿enie
adiponektyny u chorych na RRMS w porównaniu z grup¹
kontroln¹ (p < 0,0001). Odsetek komórek nTreg (p < 0,01)
i wskaŸnik œredniej intensywnoœci fluorescencji (MFC) dla
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the transcription factor Foxp3 nTreg in patients with RRMS
(r = –0.7, p < 0.05).
Conclusions: Proinflammatory adipocytokine profile and
decreased percentage of nTreg cells suggest their implication
in the inflammatory response in RRMS regardless of corti-
costeroid therapy. The correlation between leptin and the
MFC of the transcription factor Foxp3 in nTreg cells in
patients with RRMS suggests its inhibitory effect on FoxP3
expression. 
Key words: multiple sclerosis, leptin, resistin, adiponectin,
natural regulatory T cells (nTreg), FoxP3. 
FoxP3 (p < 0,001) by³y znamiennie mniejsze u chorych na
RRMS. Stwierdzono ujemn¹ korelacjê pomiêdzy stê¿eniem
leptyny a MFC dla czynnika transkrypcyjnego FoxP3 w lim-
focytach nTreg u chorych na RRMS (r = –0,7; p < 0,05).
Wnioski: Prozapalny profil adipocytokin i zmniejszenie odset-
ka limfocytów nTreg sugeruje ich udzia³ w przebiegu reak-
cji zapalnej u chorych na RRMS niezale¿nie od terapii 
kortykosteroidami. Korelacja pomiêdzy stê¿eniem leptyny
i wskaŸnikiem MFC dla czynnika transkrypcyjnego FoxP3
w limfocytach nTreg u chorych na RRMS wskazuje na 
ha muj¹cy wp³yw leptyny na jego ekspresjê.
S³owa kluczowe: stwardnienie rozsiane, leptyna, rezystyna,
adiponektyna, naturalne limfocyty regulatorowe (nTreg),
FoxP3. 
Introduction
Multiple sclerosis (MS) is an organ-specific autoim-
mune disorder with typical multifocal inflammatory
lesions (plaques) located mostly in the white matter of
the brain and spinal cord, leading to demyelination and
neurodegeneration [1,2]. Pathogenesis of the disease 
is not fully understood but the available data suggest that
during the course of MS an autoimmune reaction occurs
with autoreactive T cells passing through the blood-brain
barrier and entering the central nervous system [3].
It was thought initially that the development 
of the disease was predominantly related to the CD4+
lymphocytes with Th1 cytokine profile, which are res -
ponsible for the secretion of proinflammatory cytokines
[1,2,4]. However, subsequent studies showed that 
the immunopathogenesis of MS involves many other
lymphocyte subpopulations, e.g. T helper 17 cells
(Th17), natural regulatory T cells (nTreg), Treg type 1
(Tr1) cells, as well as mediators secreted by those cells
[1,5-7].
nTreg lymphocytes comprise 5-10% of all CD4+ T
lymphocytes in peripheral blood. They are thought to
be the major subpopulation of cells responsible for the
maintenance of immunological homeostasis. These lym-
phocytes can suppress the proliferation and cytokine
secretion by effector CD4+, CD8+, monocytes, NK
cells, and dendritic cells. The major discovery related to
nTreg lymphocytes was the identification of transcrip-
tion factor Foxp3, which is believed to be essential for
the differentiation and functioning of this subpopula-
tion [8-12]. Many reports suggest that the autoimmu -
nological disorders, including MS, are characterized by
impaired suppressor function of nTreg CD4+ that leads
to the decreased expression of the transcription factor
FoxP3 [3,11,13].
Recently, attention has been paid to the close asso -
ciation between inflammation and adipose tissue, where
some adipocytokines, namely leptin, resistin and adi -
ponectin, are synthesized [14-17]. The impact of lep-
tin on immunological function is well known. Leptin
induces the proliferation of T lymphocytes, production
of cytokines, mainly interleukin (IL)-1, IL-12, tumour
necrosis factor (TNF)-α, activation of monocytes and
macrophages, and phagocytosis [15,17-21]. It was also
shown that macrophages and T lymphocytes infiltrat-
ing the area of inflammatory process in experimental
autoimmune encephalomyelitis (EAE) might be the
source of leptin [1,5,16,21].
It is believed that resistin probably comes from
monocytes and macrophages, and to a lesser extent, from
adipocytes [15,22-24]. Increased concentrations of that
protein were found in obese subjects, mostly during
acute inflammatory reactions and after stimulation with
some cytokines, i.e. TNF-α, IL-1, IL-6 [7,17,22,23].
In contrast to leptin and resistin, adiponectin is
thought to be an important anti-inflammatory factor
[17,24]. It suppresses the activation and proliferation
of T and B lymphocytes, as well as synthesis of proin-
flammatory cytokines (IL-6, TNF-α, INF-γ), and
induces synthesis of the anti-inflammatory cytokine 
IL-10 [7,15,17].
Recent data suggest that leptin and nTreg may play
a pivotal role in the immunopathogenesis of MS and the
associated inflammation. Thus, the purpose of this study
was to evaluate selected adipocytokines and nTreg cells
and to assess their relationship with RRMS.
Adipocytokines and natural regulatory T cells in MS
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Material and methods
The study included 25 patients (16 women and 9 men,
mean age 40.3 ± 13.1 years) and 25 healthy controls
(16 women and 9 men, mean age 38.5 ± 6.5 years).
Patients were diagnosed with RRMS according to the
McDonald criteria, with the use of two-phasic magne -
tic resonance imaging (MRI) of the head, analysis of
the cerebrospinal fluid and assessment of visual evoked
potentials [25]. The Expanded Disability Status Scale
score in each patient was ≤ 3.5.
Patients with disorders mimicking MS with their
clinical picture or MRI findings, e.g. with vascular col-
lagen disorders, neuroborreliosis and neuroinfections,
were excluded. Peripheral blood was drawn for testing
within two weeks after the onset of acute MS relapse.
MS relapses were treated routinely with corticosteroids
(intravenous methylprednisolone, 1 g daily, followed by
tapered oral corticosteroids).
The protocol of the study was approved by the Bio -
ethical Committee at the Medical University of £ódŸ
(decision no. RNN/19/09/KE). 
Body mass index (BMI) was calculated, based on
patients’ body weight and height (Table 1).
Concentrations of adipocytokines were measured 
in sera with ELISA immunoenzymatic tests (leptin –
LEPTIN ELISA, DRG Diagnostic, resistin –
QUANTIKINE human Resistin, R&D Systems, and
adiponectin – QUANTIKINE human Adiponectin,
R&D Systems). Colour intensity was measured spec-
trophotometrically with ELISA reader ELx800 at the
wavelength of 450 nm.
Immunophenotyping of nTreg isolated from peri -
pheral blood was performed with eight-colour flow
cytometer BD FACS CANTO II. The following mo -
noclonal antibodies were used to stain the nTreg sub-
populations: anti-human CD4 conjugated to Pacific
Blue (RPA-T4 clone), anti-human CD25 conjugated to
FITC (M-A251 clone), anti-human CD127 conjugat-
ed to PE (HIL-7R-M21 clone), anti-human FoxP3
conjugated to Alexa 647 (259D/C7 clone). All anti-
bodies were purchased from BD Pharmingen. Staining
of the superficial antigens was performed according to
the manufacturer’s suggested procedure (BD Bio-
science). Staining of the intracellular transcription fac-
tor FoxP3 was performed after the permeabilization of
cells, according to the manu facturer’s suggested proce-
dure (BD Bioscience).
Analysis of expression of particular antigens and
mean fluorescence intensity measured as mean fluores-
cence channel (MFC) was performed with the use of
FACS DIVA v.6.2 software.
For each tube, lymphocytes were gated according 
to Forward Scatter (FSC) and Side Scatter (SSC) para-
meters. The second gate was set for the subpopulation
of CD4+. Then, the gates for nTreg lymphocytes were
set according to the phenotype D4+CD25highCD127low
FoxP3+.
The results were analysed statistically with the 
STATISTICA v. 8.0 PL software. Variables were
assessed regarding the distribution and equality of va -
riances. Quantitative variables were characterized with
median, lower and upper quartile. Comparisons of stud-
ied features between groups were performed with
Mann-Whitney U-test. Correlations were assessed with
the Spearman correlation rank coefficient. A p-value 
< 0.05 was considered significant.
Results
Anthropometric data showed that the BMI was 
simi lar in patients with MS and in controls. No differ-
ence regarding BMI was found between patients and
controls in relation to sex (Table 1).
The concentration of leptin was significantly, three
times greater in patients with RRMS than in controls 
(p < 0.0001) (Table 2). The concentration of resistin in
patients with RRMS was two times greater than in con-
trols (p < 0.0001) (Table 2). On the other hand,
adiponectin concentration was three times smaller in
patients with RRMS than in controls (p < 0.0001)
(Table 2).
Patients with RRMS Controls
Total Women Men Total Women Men
n = 25 n = 16 n = 9 n = 25 n = 16 n = 9
BMI [kg/m2] 23.8 23.8 24.2 24.3 24.3 24.3
22.4-24.8 22.7-25.2 22.4-24.2 23.6-24.8 23.1-24.9 23.9-24.7
Table 1. Body mass index (BMI) of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy subjects. Quantitative variables are presented as median,
lower and upper quartile
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The percentage of nTreg was assessed according to
the expression of the most specific markers for this sub-
population, namely CD4+CD25highCD127lowFoxP3+.
It was significantly lower in patients with RRMS when
compared with controls (p < 0.01) (Table 3). MFC ratio
for FoxP3 transcription factor was also significantly low-
er in patients with RRMS than in controls (p < 0.001)
(Table 3).
An inverse correlation between leptin concentration
and MFC ratio for FoxP3 transcription factor was
found in patients with RRMS (Spearman r = –0.7; 
p < 0.05). Significant correlations were found neither
between resistin or adiponectin concentration and MFC
ratio nor between adipocytokine concentration and the
percentage of nTreg in studied groups.
Discussion
Multiple sclerosis with its underlying inflammatory
process and autoimmunological disturbances has been
a focus of extensive research for many years. The course
of MS is most often relapsing-remitting or secondary
progressive; rarely, primary progressive or benign form
occurs [26]. The disease affects young people, pre-
dominantly in developed countries (United States, Cana-
da, Scandinavian countries). MS poses significant social,
economic, and most of all clinical problems [2]. Cur-
rent management includes mainly corticosteroids for
rela pses and immunomodulation (interferon β, copoly-
 mer-1, immunosuppressive agents) for chronic forms.
Despite improved methods of treatment, the disease is
incurable [2]. Therefore, new possibilities for the mod-
ulation of the inflammatory process and the involved
cells are actively sought which may lead to new options
of targeted intervention.
The influence of adipocytokines on Treg and effec-
tor T cells (Teff) has been highlighted [27]. Some of
these proteins (leptin, resistin) induce proinflammato-
ry processes, while others (adiponectin) have protective,
anti-inflammatory properties [24]. The concentration
of adipocytokines in blood is obviously related to the
adipose tissue amount, indirectly assessed by BMI. 
It was shown previously that obesity, especially of the
visceral type, accompanied the presence of a chronic 
subclinical inflammatory process, which is responsible
for activation of proinflammatory pathways [7]. In our
study, BMI in patients with MS was comparable to that
in controls. These findings suggest that the difference
in adipocytokine concentrations in patients with MS in
comparison to controls cannot be attributed to the adi-
pose tissue amount, but instead it may result from the
ongoing illness with an intense and active inflammato-
ry background.
It was shown that treatment with corticosteroids can
affect the concentration of adipocytokines. However, the
available data are equivocal. Cimmino et al. found that
the observed changes in adiponectin level in MS patients
treated with prednisone were related more to the inflam-
mation than to the corticosteroid itself, while the increase
of leptin level depended on corticosteroids with the 
synchronous decrease of inflammatory markers (ESR,
CRP, IL-6). Those authors also observed a correlation
between the level of endogenous or exogenous steroid
and the concentration of leptin [28]. It should be
stressed, however, that other authors quite commonly
have reported contrary findings; thus, it is thought that
the most probable cause of increased adipocytokine 
levels is the inflammatory process, not corticosteroids,
although the influence of corticosteroids cannot be clear-
ly excluded. 
Increased leptin concentration in patients with
RRMS is in accordance with the findings published pre-
viously [5,18,21,27,29]. Frisullo et al. [14] noted an
increased leptin level in the active phase of RRMS in
untreated patients when compared to controls. Matarese
et al. reported increased levels of that adipocytokine both
Variable Patients with RRMS Controls
n = 25 n = 25
Leptin [ng/mL] 19.9 4.5
12.0-21.5 1.6-8.6
Resistin [ng/mL] 7.1 3.5
4.7-9.3 2.7-4.4
Adiponectin [ng/mL] 41.6 119.6
17.8-53.5 74.3-193.4
Table 2. Concentrations of adipocytokines in patients with relapsing-remitt-
ing multiple sclerosis (RRMS) and in healthy subjects. Quantitative variables
are presented as median, lower and upper quartile
Patients with RRMS Controls
nTreg % 4.4 7.5
2.2-4.9 3.9-9.3
MFI FoxP3 335 580
260.0-345.0 563.0-800.0
Table 3. Percentage of natural regulatory T lymphocytes (nTreg)
CD4+CD25highCD127lowFoxP3+ and mean fluorescence channel (MFC) 
of the transcription factor Foxp3 in patients with relapsing-remitting multi-
ple sclerosis (RRMS) and controls. Variables are presented as median, lower
and upper quartile
Adipocytokines and natural regulatory T cells in MS
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in serum and in cerebrospinal fluid of untreated patients
with RRMS [21,27]. Batocchi et al. showed that the
serum concentration of leptin markedly decreased after
two-month therapy with interferon beta. Those reports
confirm the association between leptin and the activity
of the process in patients with MS [18]. Frisullo et al.
[14] additionally observed a modulatory effect of lep-
tin during the relapses, where its use stimulated pro-
duction of TNF-α and IL-6.
Studies show that resistin also plays an important
role in inflammation, and the major sources of it are
mononuclear cells: monocytes and macrophages [16,22-
24]. Our study showed that the resistin level was two
times greater in patients with RRMS than in controls.
There are no reports on the role and significance of that
marker in serum or in cerebrospinal fluid in patients
with MS. Recently reported studies on the role of
resistin in many other acute and chronic conditions relat-
ed to inflammation (kidney diseases, inflammatory 
bowel disease, liver diseases) have shown a correlation
between the level of this protein and exacerbation of the
disorder [16,22,23]. The proinflammatory cytokines
IL-1, IL-6 and TNF-α increase expression of mRNA
of the resistin gene in mononuclear blood cells. On the
other hand, resistin, through activation of the NF-κB
pathway, stimulates the production of those proinflam-
matory cytokines [15,22].
It is known that adiponectin has potential anti-
inflammatory properties. It suppresses the synthesis of
proinflammatory cytokines (TNF-α, IL-6, INF-γ) and
therefore has some protective function against the deve-
lopment of numerous inflammatory conditions. It was
shown that its concentration in obese subjects was small
and inversely correlated with markers of inflammation
(CRP and IL-6) [7,15,16,24]. Data on the beneficial,
anti-inflammatory action of adiponectin come from stud-
ies in patients with obesity, coronary heart disease, insulin
resistance, and diabetes [15,17,24].
We noted a significantly smaller (three times small-
er) concentration of that adipocytokine in patients with
RRMS when compared with controls. The direction of
those changes probably reflects the imbalance of the
immunological status promoting the proinflammatory
Th1 cytokine profile during acute relapse of MS.
The observed two times greater resistin concentra-
tion and three times smaller adiponectin concentration
seem to be the result of the inflammatory process. 
The impact of therapy with corticosteroids on resistin
and adiponectin levels cannot be excluded, but there are
no data in the literature related to that problem.
A subpopulation of nTreg CD4+CD25highCD127low
FoxP3+ has become an important target of studies on
autoimmune disorders because it is responsible for
immunological tolerance. It was confirmed that dys-
function of these cells might have a close relation to the
pathogenesis of the autoaggressive disorders. The sig-
nificance of nTreg in human autoimmunological disor-
ders is not fully understood but several lines of clinical
and experimental evidence support its major role in
abnormal immunological tolerance. Abnormalities in the
nTreg population along with Tr1 and Th3 lymphocyte
subpopulations are most commonly reported. The rela-
tionship between nTreg dysfunction and the occurrence
of the disorder was reported for type 1 diabetes mellitus,
gastritis, colitis and thyroiditis [1,4]. The tendency to
greater prevalence of autoimmune disorders was also not-
ed in cases with deletion of 22q11 associated with thy-
mus atrophy. Apart from MS, dysfunction of nTreg has
been reported in myasthenia, rheumatoid arthritis, pso-
riasis, and polyglandular autoimmune syndrome type 2
[5]. Our study showed that patients with RRMS 
had a smaller percentage of Treg CD4+CD25high
CD127lowFoxP3+ cells in peripheral blood and a lower
MFC value for transcription factor FoxP3. These
changes might result in decreased suppressor function. 
Data related to the nTreg subpopulation in MS are
contradictory. Kumar et al. observed an increased size
of this lymphocyte subpopulation. Putheti and Feger, on
the other hand, did not find important differences in the
number of regulatory CD4+ T cells in peripheral blood
[11,30,31]. Viglietta et al. [12] observed both decreased
number and dysfunction of Treg in the course of MS.
Feger et al. [11] noted an increased number of Treg
lym pho cytes in cerebrospinal fluid of patients with MS.
The majority of reports confirm the dysfunction of Treg
and decreased expression of FoxP3 transcription factor
in nTreg lymphocytes in patients with RRMS; this form
of MS involves an important role of adipocytokines as
me diators of the inflammatory process. Such changes
were not observed in chronic forms of the disease
[11,12,32,33].
More and more often, the pathogenesis of autoag-
gressive disorders, including MS, is being associated
with the abnormal regulatory function of induced Tr1
lymphocytes, which is related to the change in expres-
sion of the cytoplasmic form Cyt2-CD46 [9,10].
Data on the relationship between adipocytokine con-
centration and nTreg lymphocytes are scarce. De Rosa
et al. unequivocally demonstrated an association between
leptin and nTreg and increase of the autoaggressive
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process. The regulatory lymphocytes themselves can be
the source of that adipocytokine, which suggests its auto -
crine function. Thus, leptin may potentiate the inflam-
matory process through the induction of synthesis and
secretion of IL-2, IL-6, INF-γ, TNF-α [4,7,14,19,29],
and, on the other hand, by the induction of anergy of
the CD4+CD25+ lymphocyte subpopulation [5,6,20].
Numerous studies highlight the major role of both
leptin and Treg lymphocytes in the autoimmune process
with the underlying inflammation. It is true also for
RRMS. The obtained results suggest that dysfunction
of nTreg and exacerbation of the inflammatory process
occur in patients with MS during relapse. Surprising-
ly, the decreased nTreg subpopulation and decreased
expression of FoxP3 transcription factor in nTreg 
was found despite the therapy with corticosteroids. Both
our previous studies and reports of other authors sug-
gest that glucocorticoids cause increased expression of
FoxP3 transcription factor [34,35]. Markedly increased
concentrations of proinflammatory adipocytokines (lep-
tin and resistin) and decreased concentrations of anti-
inflammatory adiponectin were noted simultaneously.
To sum up, this study showed neither a correlation
between resistin and adiponectin levels and MFC ratio for
FoxP3 transcription factor, nor a correlation between
adipocytokine and the percentage of nTreg in the studied
groups. The inverse correlation found between leptin con-
centration and MFC value for FoxP3 transcription factor
suggests a possible influence of leptin on FoxP3 expres-
sion. The results of our study show an important modula-
tory potential of adipocytokines and nTreg in RRMS.
Conclusions
1. Proinflammatory adipocytokine profile and decreased
percentage of nTreg cells suggest their implication in
the inflammatory response in RRMS regardless of
corticosteroid therapy.
2. The correlation between leptin and the MFC of the
transcription factor Foxp3 in nTreg cells in patients
with RRMS suggests its inhibitory effect on FoxP3
expression. 
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